Editorial Office, Journal of Health and Medical Research, Belgium
Perspective
Immune Checkpoint Inhibitors as a Treatment for Hepatocellular Carcinoma in the Early Stages Before Liver Transplantation
Author(s): Herlin Jones*
Hepatocellular Carcinoma (HCC) is one of the most frequent cancers in the world, and its frequency is on the rise. This review examines the present and expanding amount of evidence on the use of immune checkpoint inhibitors in patients with advanced HCC who are awaiting liver transplantation, as well as many of the unanswered concerns. Immunotherapy clearly has a function in HCC, and more clinical trials will assist to define the indications and criteria for its usage. Hepatocellular Carcinoma (HCC) is the most frequent kind of liver cancer and the third greatest cause of mortality from cancer in the world. Liver-directed medications for locoregional control or down-staging prior to final surgical therapy with hepatic resection or liver transplantation have been extensively explored and are the pillars of current treatment recommendations for early and intermediate-stage illness. Our .. View More»
DOI:
10.37532/jhmr.2022. 4(3).113
